RT Journal Article
SR Electronic
T1 Pulmonary manifestations of antiphospholipid syndrome: A retrospective analysis of 67 patients
JF European Respiratory Journal
JO Eur Respir J
FD European Respiratory Society
SP OA3803
DO 10.1183/13993003.congress-2018.OA3803
VO 52
IS suppl 62
A1 Sevinc Sarinc Ulasli
A1 Deniz Köksal
A1 Oguz Karcioglu
A1 Berkan Armagan
A1 Alper Sari
A1 Elif Babaoglu
A1 Ali Akdogan
A1 Sule Apras Bilgen
YR 2018
UL http://erj.ersjournals.com/content/52/suppl_62/OA3803.abstract
AB Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by arterial and/or venous thrombosis accompanied by persistently elevated levels of antiphospholipid antibodies. We aimed to evaluate pulmonary manifestations of APS.Method: We retrospectively reviewed the data of patients who were followed in the department of rheumatology with the diagnosis of APS between October 2010 and May 2017. Demographic data, clinical, radiological and laboratory findings were recorded.Results: The study included 67 patients (56 female/11 male) with a mean age of 39±13 years. Pulmonary manifestations such as parenchymal and/or vascular involvement were seen in 12 (17.9%) patients. There were no significant differences between patients with and without pulmonary manifestations in terms of age (p=0.46), comorbidities (p=0.48) and APS duration (p=0.661). Acute pulmonary thromboembolism (PE) was determined in 11 (16.4%), alveolar hemorrhage in 2 (3%) patients. Four patients with acute PE (36%) developed chronic thromboembolic pulmonary hypertension (CTEPH). One patient developed both CTEPH and diffuse alveolar hemorrhage after acute PE during follow up. Antiphosholipid antibody IgM was highly positive in patients with PE compared to patients without PE (p=0.005). Other antiphosholipid antibodies and lupus anticoagulant were not significantly different in patients with and without PE. None of the patients were deceased due to pulmonary manifestations of APS.Conclusion: PE was the most common pulmonary manifestation of APS. The development of CTEPH was high among APS patients. Patients with APS should be closely followed for the onset of PE and CTEPH.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, OA3803.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).